On April 8, 2024, Seres Therapeutics, Inc announced that it has held its annual general meeting of shareholders on April 4, 2024, and declared voting results. Accordingly, a stockholder proposal on simple majority vote from Kenneth Steiner was approved by the shareholders of the Company.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.025 USD | +36.78% | -8.11% | -27.14% |
06:02pm | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
12:32pm | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.14% | 113M | |
+3.33% | 108B | |
+10.43% | 105B | |
+1.57% | 23.46B | |
-13.04% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-7.35% | 17.19B | |
+5.89% | 13.99B | |
+36.69% | 12.53B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Declaration of Voting Results by Seres Therapeutics